載入中
NASDAQHealthcareBiotechnology
最新資料
US$0.764
−US$0.035 · -4.38%
Rani Therapeutics Holdings, Inc. functions as a clinical-stage biopharmaceutical enterprise focused on revolutionizing the delivery of biologic therapies through oral administration. Its flagship innovation, the RaniPill capsule, aims to supplant conventional subcutaneous or intravenous injections of biologics with a more convenient oral dosing method. The company maintains a comprehensive portfolio of investigational treatments. Among these is RT-101, an octreotide, which has progressed beyond Phase I clinical trials for the management of neuroendocrine tumors and acromegaly. Another promising candidate is RT-105, an anti-TNF-alpha antibody designed to address psoriatic arthritis. Additionally, RT-102, a parathyroid hormone for osteoporosis, is currently advancing through preclinical studies. Other therapies under development include RT-109, a human growth hormone for treating growth hormone deficiency; RT-110, a parathyroid hormone aimed at hypoparathyroidism; and RT-106, a basal insulin formulated for type 2 diabetes. Established in 2012, the company's corporate base is located in San Jose, California.
一般交易時段
US$0.764
−US$0.035 · -4.38%
盤中時間採用ET。市場資料可能有所延遲。
Rani Therapeutics Holdings, Inc. functions as a clinical-stage biopharmaceutical enterprise focused on revolutionizing the delivery of biologic therapies through oral administration. Its flagship innovation, the RaniPill capsule, aims to supplant conventional subcutaneous or intravenous injections of biologics with a more convenient oral dosing method. The company maintains a comprehensive portfolio of investigational treatments. Among these is RT-101, an octreotide, which has progressed beyond Phase I clinical trials for the management of neuroendocrine tumors and acromegaly. Another promising candidate is RT-105, an anti-TNF-alpha antibody designed to address psoriatic arthritis. Additionally, RT-102, a parathyroid hormone for osteoporosis, is currently advancing through preclinical studies. Other therapies under development include RT-109, a human growth hormone for treating growth hormone deficiency; RT-110, a parathyroid hormone aimed at hypoparathyroidism; and RT-106, a basal insulin formulated for type 2 diabetes. Established in 2012, the company's corporate base is located in San Jose, California.
日內區間
目前US$0.764
52週區間
目前US$0.764
盤中時間採用ET。市場資料可能有所延遲。
Rani Therapeutics Holdings, Inc. functions as a clinical-stage biopharmaceutical enterprise focused on revolutionizing the delivery of biologic therapies through oral administration. Its flagship innovation, the RaniPill capsule, aims to supplant conventional subcutaneous or intravenous injections of biologics with a more convenient oral dosing method. The company maintains a comprehensive portfolio of investigational treatments. Among these is RT-101, an octreotide, which has progressed beyond Phase I clinical trials for the management of neuroendocrine tumors and acromegaly. Another promising candidate is RT-105, an anti-TNF-alpha antibody designed to address psoriatic arthritis. Additionally, RT-102, a parathyroid hormone for osteoporosis, is currently advancing through preclinical studies. Other therapies under development include RT-109, a human growth hormone for treating growth hormone deficiency; RT-110, a parathyroid hormone aimed at hypoparathyroidism; and RT-106, a basal insulin formulated for type 2 diabetes. Established in 2012, the company's corporate base is located in San Jose, California.
日內區間
目前US$0.764
52週區間
目前US$0.764
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 163.3萬 USD | 102.8萬 USD | — | — | 271.7萬 USD |
| 銷貨成本 | 90萬 USD | — | 82.2萬 USD | — | — |
| 毛利 | 73.3萬 USD | 102.8萬 USD | −82.2萬 USD | — | 271.7萬 USD |
| 研究與開發 | 2020.5萬 USD | 2668.2萬 USD | 3962.4萬 USD | 3660.7萬 USD | 2648.2萬 USD |
| 銷售、一般及管理費用 | 1973.8萬 USD | 2394.6萬 USD | 2647.5萬 USD | 2684.4萬 USD | 2783.4萬 USD |
| 營業費用 | 3904.3萬 USD | 5434.2萬 USD | 6527.7萬 USD | 6345.1萬 USD | 5431.6萬 USD |
| 利息收入 | 82.7萬 USD | 176.3萬 USD | 330.1萬 USD | 124.8萬 USD | 8.9萬 USD |
| 利息支出 | 289.1萬 USD | 503.3萬 USD | 508.5萬 USD | 107.1萬 USD | 46.6萬 USD |
| 折舊和攤銷 | 90萬 USD | 102.8萬 USD | 82.2萬 USD | 54.8萬 USD | 49.7萬 USD |
| 營業利益 | −3831萬 USD | −5331.4萬 USD | −6609.9萬 USD | −6345.1萬 USD | −5159.9萬 USD |
| 淨利 | −2967.3萬 USD | −3001.8萬 USD | −3397萬 USD | −3058.8萬 USD | −833.1萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$15.67
上漲空間 1951.05%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI311.36萬0.00%2.3兆 USD0.03%US$381.28-0.17%
Vanguard Extended Market ETFVXF71.28萬0.00%954億 USD0.05%US$233.58-0.61%
Invesco Nasdaq Biotechnology ETFIBBQ6627.710.01%1.12億 USD0.19%US$34.265-1.03%
ProShares Ultra Nasdaq BiotechnologyBIB3542.770.00%9320.36萬 USD1.19%US$108.95-1.83%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFInvesco Nasdaq Biotechnology ETFIBBQProShares Ultra Nasdaq BiotechnologyBIBAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
